NEW YORK (GenomeWeb News) – ParagonDx said today that it has received US Food and Drug Administration clearance to market its rapid genotyping assay for warfarin sensitivity.
 
The pharmacogenomic test provides information about the CYP2C9 and VKORC1 genotypes and is used to identify patients that are at greater risk for warfarin sensitivity. ParagonDx claimed in a statement that its product is the first cleared genotyping assay to deliver results in less than an hour and incorporate human genomic quality controls.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.